5Raggatt LJ,Partridge NC.HMG-COA reductase inhibitors as immunomodulators:potential use in transplant rejection[J].Drugs,2002,62:2185-2191.
6Farmer JA.Learning from the cerivastatin experience[J].Lan cet,2001,358:1383-1385.
7Silver MA.Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction[J].Am J Cardiol,2004,94:1306-1310.
9Nawarskas JJ.HMG-CoA reductase inhibitors and coenzyme Q10[J].Cardiol Rev,2005,13:76-79.
10Lankin VZ,Tikhaze AK,Kukharchuk VV,et al.Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins[J].Mol Cell Biochem,2003,249:129-140.
二级参考文献27
1Goode GK, Heagety AM. In vitro responese of human peripheral small arteries in hypercholesterolemia and effects of therapy[J].Circulation,1995,91:2898-2903.
2Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension[J].N Engl J Med,1990,323:22-27.
3Sack FM, Pfetter MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patient with average cholesterol levels[J].N Engl J Med,1996,335:1001-1009.
4Dobrucki W, Kalinowskil L. Statin-stimulated nitric oxide release from endothelium[J].Med Sci Monit,2001,7:622-627.
5Kureishi Y, Luo Z, Shiojioma I, et al. The HMG-CoA reductase inhibitor sirastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals[J].Nat Med,2000,6:1004-1010.
6Gloriose N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia[J].Hypertension,1999,34:1281-1286.
7Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J].Hypertension,2001,137:1450-1457.
8Hedblad B, Wildstraand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness[J].Circulation,2001,103:1721-1726.
9Atherosclerosis research unit effect of atorvastatin on postprandial plasma lipoproteins in postinfaction patients with combined hyperlipidemia[J].Atherosclerosis,2002,162:163-170.
10Vansant G,Mertens A,Muls E.The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozy gous for apoE3[J].Acta Cardiol,2001,56:149-154.
1Cholesterol Treatment Trialists (CTY) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective recta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet, 2005, 366: 1267-1278.
4Law M, Rudnicka AR .Statin safety: a systematic review. Am J Cardiol, 2006, 97: 52C-60C.
5Famularo G, Minisola G, Gasbarrone L. Comment and reply on: atorvastatin: safety and tolerability, statins and polymyositis: a neglected link. Expert Opin Drug Saf, 2010, 9: 1005-1006.
6Fauchais AL, Iba BJ, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs five cases. Rev Med Interm, 2004, 25: 294-298.
7Nicola G, Marco S, Giancarlo M, et al. Polymyositis associated with simvastatin. Lancet, 1997, 349: 1600-1601.
8Rieseo EG, Arpa-Gutierrez FJ, Gutierrez M, et al. Severe polymyositis with simvastatin use. Rev Neurol, 2003, 37: 934- 936.
9Takagi A, Shiio Y polymyositis: a case report. Rinsho Shinkeigaku, 2004, 44: 25-27.
10Rodriguez GJ, Serrano CM. Lovastatin-associated dermatomyosi- tis. Postgrad Med J, 1996, 72: 694.
